Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
BSX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$65.34 - $107.17
Previous CloseN/A
Volume5.49M
Average Volume (3M)6.22M
Market Cap
$155.27B
Enterprise Value$144.04B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)84.7
Beta0.72
Next Earnings
Apr 23, 2025EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.25
Shares Outstanding1,475,778,100
10 Day Avg. Volume5,965,950
30 Day Avg. Volume6,224,744
Standard Deviation0.07
R-Squared0.41
Alpha0.00756
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.76
Price to Cash Flow (P/CF)38.70
P/FCF Ratio44.20
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.54
Enterprise Value/Ebitda38.59
Forecast
1Y Price Target
$118.95Price Target Upside12.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBoston Scientific reported strong revenue growth for Q4, surpassing both analyst estimates and consensus figures, highlighting a successful year for the company.
Market ExpansionLabel expansion into persistent AF would open access to an additional 150-200k advanced atrial fibrillation US cases per year, increasing market opportunities.
Product InnovationThe rate of adoption and utilization of pulsed field ablation (PFA) technologies will continue to exceed expectations, indicating strong demand and growth potential.
Bears Say
Future Growth ChallengesFuture growth is expected to decelerate following a strong year, which may pose challenges for current valuations and potential upside.
Growth ExpectationsFuture growth is expected to decelerate following a strong year, which may pose challenges for current valuations and potential upside.
Market ConditionsDespite expectations of slower growth, Boston Scientific is likely to remain appealing to investors due to its momentum and strategic M&A activities in the Med-Tech space.
---
Ownership Overview
0.19% Insiders
29.47% Mutual Funds
19.00% Other Institutional Investors
31.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $65.33 and its highest was $107.17 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $155.27B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Apr 23, 2025 which is in 61 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Feb 05, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.657 by $0.043.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.67.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,475,778,100 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.7 in its last earnings report, beating expectations of $0.657. Following the earnings report the stock price went up 1.381%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in BSX
---
Boston Scientific Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$118.95 (12.90% Upside)
$118.95 (12.90% Upside)
Blogger Sentiment
Bullish
BSX Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.54%
12-Months-Change
Fundamentals
Return on Equity
8.51%
Trailing 12-Months
Asset Growth
12.12%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.
---
BSX Company Deck
---
BSX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong operational and financial performance with significant growth in key areas such as electrophysiology and Watchmen sales. Despite challenges in China and currency impacts, the company exceeded its financial guidance and demonstrated solid strategic execution.Read More>---
BSX Revenue Breakdown
64.22% Cardiovascular
35.79% MedSurg
---
BSX Stock 12 Month Forecast
Average Price Target
$118.95
▲(12.90% Upside)
Technical Analysis
Abbott Laboratories
―
Intuitive Surgical
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Best Analysts Covering BSX
1 Year
1 Year Success Rate
22/22 ratings generated profit
1 Year Average Return
+35.50%
reiterated a buy rating 16 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +35.50% per trade.
---